Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Saved in:
| Title: | Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. |
|---|---|
| Authors: | Singh, Dave1 (AUTHOR) dsingh@meu.org.uk, Balaguer, Victor2 (AUTHOR), Astbury, Carol2 (AUTHOR), Wählby-Hamrén, Ulrika3 (AUTHOR), Jimenez, Eulalia4 (AUTHOR), Seoane, Beatriz5 (AUTHOR), Villarroel, Cristina6 (AUTHOR), Lei, Alejhandra7 (AUTHOR), Aggarwal, Ajay8 (AUTHOR), Psallidas, Ioannis9 (AUTHOR) |
| Source: | Respiratory Research. 9/9/2020, Vol. 21 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14659921 |
|---|---|
| DOI: | 10.1186/s12931-020-01347-7 |
